Date: 2015-11-04
Type of information: Licensing agreement
Compound: tavilermide (MIM-D3) Topical Dry Eye
Company: Allergan (Ireland) Mimetogen Pharmaceuticals (Canada)
Therapeutic area: Ophtalmological diseases
Type agreement: licensing
Action mechanism: protein. Tavilermide is a small cyclic peptidomimetic of NGF (Nerve Growth Factor), a naturally occurring protein in the eye responsible for the maintenance of corneal nerves and epithelium. Tavilermide is differentiated from other investigational therapies in dry eye disease because it induces the production of mucin, a naturally occurring component of the tear film, and works upstream prior to inflammation.
Disease: dry eye disease
Details: * On November 4, 2015, Allergan announced that its wholly owned subsidiary has entered into an exclusive licensing agreement with Mimetogen Pharmaceuticals , a clinical stage biotechnology company, to develop and commercialize tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease.
In a previously announced Phase 2 trial (Study Designation MIM-725) tavilermide demonstrated significant improvements in both signs and symptoms with 1% tavilermide versus placebo, together with strong safety, comfort and tolerability profiles. Tavilermide is currently being evaluated in two multi-center Phase 3 clinical studies in the United States for the treatment of dry eye disease.
Financial terms: Under the terms of the agreement, Allergan will make an upfront payment of $50 million to Mimetogen and will fund phase 3 development of tavilermide. Mimetogen will additionally be entitled to receive potential milestone payments and royalties based on commercialization of the product.
Latest news:
